News

Filter By:

  • All
  • Blog
  • In the News
  • Press Releases
  • Publications
All
  • All
  • Blog
  • In the News
  • Press Releases
  • Publications
Press Releases

Dyno Therapeutics Named on the Forbes List of America’s Best Startup Employers 2022

BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. …

Read More →
Blog

Hera – the missing Argo Workflows Python SDK

At Dyno, we believe in collective innovation on our journey of empowering a diverse team of the best problem solvers to drive cutting edge science …

Read More →
In the News

Dyno Therapeutics at Goldman Sachs Byte-ology Conference

Discussing the Convergence of Biotechnology and Technology  Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman …

Read More →
In the News

Dyno Therapeutics Named Emerging Company of the Year at New England Venture Capital Association’s 2021 NEVY Awards

  BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life …

Read More →
In the News

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 – Astellas Pharma Inc. (TSE: …

Read More →
Blog

Our Focus on Mission Driven Collective Innovation

Dyno empowers a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. Our mission is to build the ideal capsid …

Read More →
In the News

The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home

These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.

Read More →
Blog

Introduction to AAV as a Gene Therapy Vector, Part 2

What are AAVs? and what makes them good candidates for gene therapy? By: Christopher Reardon, Stephen Malina, and Eryney Marrogi Introduction In the first part …

Read More →
In the News

Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months

Every day seems to bring a fundraising record and a new company launching in the biotech industry. Insider spoke with some of the smartest and most plugged-in venture capitalists in biotech to pinpoint the most exciting startups.

Read More →
Blog

Introduction to AAV as a Gene Therapy Vector, Part 1

What are AAVs? and what makes them good candidates for gene therapy? By: Stephen Malina, Eryney Marrogi, and Christopher Reardon. In two previous posts, we …

Read More →
Blog

Delivering an experience our AAViators expect through Agile work practices

At Dyno, we are empowering a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. This is easy to say …

Read More →
Press Releases

Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference

Presentations describe use of in vivo screening and machine learning to accelerate the analysis, design, and validation of improved AAV vectors.

Read More →
Blog

Dyno Therapeutics ASGCT After-Party

Please join us at the 2021 Dyno Therapeutics **ASGCT After-Party, May 13th** beginning at 7p!

Read More →
In the News

Giant steps: Dyno closes $100M series A round for advanced capsid engineering

The allocation of capital to the build-out of next-generation gene therapies continues apace. Dyno Therapeutics Inc., a leader in applying artificial intelligence to advanced capsid engineering, raised $100 million in a series A round to fund its expansion and that of its Capsidmap platform.

Read More →
In the News

Dyno raises $100 million to bring artificial intelligence to gene therapy

Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence techniques to develop gene therapies, said Thursday that it has raised $100 million from investors.

Read More →
Back to Top